- About NeuroGen
- About Stem Cell Therapy
- Virtual OPD
- Scientific Publications
- Accreditation & Awards
- International Patients
Motor neuron disease is a disease of nerves that selectively damages the nerves controlling the muscles of the body and sparing the nerves that are responsible for sensations like touch, pain, temperature and movement. It is a progressive disease and sometimes the progression is slow but it may progress very rapidly with the life expectancy of mere 3 to 5 years since diagnosis. The disease rapidly weakens every muscle in the body leaving a conscious mind trapped in a crippled body.
The term motor neuron disease encompasses different disorders. These disorders are classified based on the kind of neurons that are damaged i.e upper motor neurons or lower motor neurons and the progression of the disease. The diseases that come under the group of motor neuron disease are
The main symptom of the disease is increasing weakness of the muscles. The symptoms can begin either in Upper limbs, Lower limbs, trunk and respiratory muscles or bulbar region (Speech and swallowing). Depending upon the type of the disease progression of symptoms may vary. The symptoms start in one region and progress to other regions as the disease progresses.
Common symptoms seen in disease with lower motor neuron involvement are fasciculations in the muscles including tongue muscles that progress from one region to another. Flail muscles with progressive weakness.
Common symptoms seen in diseases with upper motor neuron involvement are severe muscles cramps. Tightness in the muscles that restricts movements causing slowness and progresses from one region to another.
Apart from this common symptoms that are observed in these diseases are –
There are no known causes of motor neuron disease. So far there have been some studies implying genetic etiology and a few genes have been identified, however the exact cause remains unknown. Some risk factors have been identified which are male gender, age above 50 years and existing family history of the disease. Some pathophysiological mechanisms like glutamate toxicity, oxidative stress and chronic inflammation have been postulated in MND.
Currently, MND is treated with a combination of medical, surgical and rehabilitative treatments. Pharmacological management consists of Riluzole. Riluzole inhibits the release and modulates the post-synaptic activity of Glutamate which is found to cause excitotoxicity in MND. It is the only medicine that has shown effect on the survival duration. With no pharmacological means of altering the disease process current management of MND is widely palliative and symptom oriented. Regular moderate intensity physical exercise with various rehabilitative therapies like physiotherapy, occupational therapy, speech therapy and respiratory therapy and in the later stages of the disease artificial ventilatory support, management of swallowing difficulty and percutaneous endoscopic gastrotomy (PEG) are routinely used.
Marked progressive axonal degeneration of motor neurons in the spinal cord and motor cortex is noted in MND. Currently the aim of stem cell therapy is to protect the existing motor neurons and attempt to bring about regeneration and repair in the damaged motor neurons. Stem cells have a potential to regenerate nerve cells as well as have a positive effect of preserving the existing nerve cells. Stem cells can effectively find their way to the site of damage and bring about successful repair and prevent further damage.
They further demonstrate immunomodulatory, anti-inflammatory and cytoprotective properties. The growth factors like vascular endothelial growth factor, secreted by these cells bring about neoangiogenesis. These paracrine effects of stem cell transplantation lead to neuroprotection and subsequent alteration in the disease course and progression.
Stem cell therapy has been shown to be beneficial in the animal studies showing improved motor function. The safety of autologous stem cells transplantation has been established and allogenic cells transplantation is being studied. Stem cell therapy has been shown to be beneficial in prolonging survival, improving respiratory function, muscle strength and bulbar impairment. It also has been shown to slow down the disease progression and rate of decline of the respiratory function. Stem cell therapy has been tested widely and has been repeatedly found to be safe and beneficial in MND.
Motor neuron disease unlike other disorders is a rapidly progressive disease and therefore the aim of stem cell therapy is to halt or slow down the progression of the disease. We conducted a study in Neurogen brain and spine institute where in the survival and rate of disease progression of patients with MND that underwent stem cell therapy was compared with the patients that did not take stem cell therapy. We found that there was significant benefit in survival which means that the survival was prolonged in patients that underwent stem cell therapy and the disease progressed slowly. The patients that were treated with stem cell therapy also found some symptomatic benefits like clearer and louder speech, improved tongue movements, reduced speech fatigability, reduced choking, improved swallowing, reduced saliva drooling, increase respiratory capacity, better neck control, better limb function, better ambulation, fine motor activities, static and dynamic standing and sitting balance.
A 38 year old female was admitted at out center with a diagnosis of definite MND according to El-escorial criteria. When she visited our center ,she had hypertonicity in all 4 limbs. Right lower extremity had severe spasticity with modified Ashworth grading of 3 while all other limbs it was 1. Voluntary control was also affected. Reflexes were exaggerated. Speech was unclear with intelligibility score of 3. She was independent in her activities of daily living with some modifications and moderate support. Functional independence measure score was 98/126. She underwent Autologous bone marrow mononuclear cells intrathecal and intramuscular transplantation 3 years after the onset of the disease. She was advised to take rilutor and a short course of Lithium for 6 weeks. She demonstrated significantly positive changes suggestive of slowing of disease progression. At 6 months due to the beneficial effects noted she underwent repeat stem cell transplantation. Frequency of falls while walking reduced from 15 – 18 times in three months to 2-3 times on three months. The voluntary control improved from fair to good. Strength of distal wrist muscles improved from grade 2++ to a functional grade of 3++ and distal hand muscles from 0 to 1. Speech was clearer and louder. Inspiratory capacity improved from 450 ml to 500 ml. It is interesting to note that the muscle strength in her distal hand muscles improved. De Carvahelo et al 2005 report a 17% decline of ALS-FRS scores every 6 months. The rate of drop of ALS-FRS score in this case was much slower suggesting slowing of disease progression. She had not deteriorated in the span of 9 months which was an improvement in itself as MND is a progressive condition and there is timely deterioration of function.